Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2019-10-18 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168 GRANTED RARE PEDIATRIC DISEASE DESIGNATION BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the FDA granting a rare pediatric disease designation to a product candidate ALMB-0168. It is an announcement of a regulatory milestone related to a drug development program, not a financial report, earnings release, or management discussion. The document is relatively short (3383 characters) and does not contain financial data or detailed report content. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a regulatory filing in the sense of compliance or certification. The content fits best as a general regulatory announcement about a significant corporate development, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2019-10-18 English
INSIDE INFORMATION - ANNOUNCEMENT ON THE INDICATIVE RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2019 OF CSPC INNOVATION PHARMACEUTICAL CO., LTD .
Regulatory Filings Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the indicative results for the nine months ended 30 September 2019 of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. It explicitly states that the financial data is preliminary, unaudited, and based on estimates. The announcement references that detailed audited results will be disclosed in the company's report for the third quarter of 2019. The document is relatively short (5750 characters) and serves to inform investors of preliminary financial performance rather than providing a comprehensive financial report with full financial statements and analysis. This fits the profile of a Capital/Financing Update (CAP) or a Regulatory Filing (RNS). However, since it is an indicative results announcement with financial performance highlights but not a full earnings release or interim report, and it is made pursuant to inside information rules, it is best classified as a Regulatory Filing (RNS) because it does not contain substantive audited financial data or detailed financial statements required for an Interim/Quarterly Report (IR) or Earnings Release (ER).
2019-10-14 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 30/9/2019. The document includes confirmations by a director regarding compliance with listing rules and legal requirements. There are no financial statements, earnings data, or management discussion of financial results. The content focuses exclusively on share capital movements and related confirmations, which aligns with announcements about share capital changes rather than full financial reports or earnings releases. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length (13,750 characters) and detailed data support it being a substantive report rather than a brief announcement or certification only.
2019-10-02 English
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "GLUTATHIONE FOR INJECTION"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the drug registration approval of a product called 'Glutathione for Injection'. It is an announcement of a regulatory approval event, not a financial report, management change, or shareholder meeting material. The document is relatively short (2682 characters) and serves as a public disclosure of a business development event. It does not contain financial data, earnings information, or detailed management discussion. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category that covers miscellaneous disclosures that do not fit other specific categories.
2019-09-26 English
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE GROUP'S "METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of a specific product, Metformin Hydrochloride Extended-Release Tablets. It is an announcement of a regulatory approval event, not a financial report, management change, or shareholder meeting material. The document is relatively short (3135 characters) and serves as a public disclosure of a product approval, which fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like financial reports or management changes.
2019-09-26 English
FIRST-IN-CLASS PRODUCT CANDIDATE ALMB-0168 WAS GRANTED ORPHAN-DRUG DESIGNATION BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of CSPC Pharmaceutical Group Limited regarding the FDA granting orphan-drug designation to a product candidate. It is a formal announcement about a regulatory milestone related to a product development, not a financial report, earnings release, or management discussion. The document is relatively short (2934 characters) and does not contain financial statements or detailed financial data. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a regulatory filing in the sense of compliance or officer certification. The content fits best with a general regulatory announcement about a significant corporate development, which falls under Regulatory Filings (RNS).
2019-09-23 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.